2026 NPPES data Medical Oncology Physician NPI 1164448734 MD
Verify on CMS →

MARK AGULNIK, MD

Medical Oncology Physician in LOS ANGELES, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
375
Medicare Part D claims · 74 beneficiaries · Medical Oncology Physician avg: 689
Generic prescribing
74%
generic claims · 26% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
99.1275/100
▲ 16 pts above national avg 83.1 · [object Object]
Industry payments
$67.7K
78 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: MARK AGULNIK, MD is a Medical Oncology Physician ([object Object]) practicing in LOS ANGELES, California with a Medicare Part D prescribing footprint of 375 claims across 74 beneficiaries — 26% brand-name prescribing . Their CMS MIPS Final Score of 99.1275/100 (national average: 83.1) reflects performance across Quality, Cost, Interoperability, and Improvement Activities . Industry payments of $67.7K across 78 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: MARK AGULNIK, MD reported a CMS MIPS final score of 99.1275 out of 100, above the 83.1 national average, and filed 375 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

MARK AGULNIK, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

MARK AGULNIK, MD at a glance

High performer (top quartile)

NPI registry status

Active

Issued 07/15/2006

NPI 1164448734

Primary specialty

Medical Oncology Physician

Niche

3,792 US NPIs in this specialty

Medicare Part D claims

375 46% vs specialty avg

2023 prescription claims

Specialty avg: 689

MIPS final score

99.1275/100 16.027500000000003% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in California

How Medical Oncology Physician compares to other specialties among California providers

California providers

Medical Oncology Physician share within California

1. Medical Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Medical Oncology Physician share within California

Medicare quality performance — MIPS

MARK AGULNIK, MD's 2023 MIPS final score plotted against the Medical Oncology Physician national average

High performer (top quartile)
MIPS Final Score
99.1275/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Medical Oncology Physician) — 99.1275/100 vs national avg 83.1

0%100%National avg83%99%
MIPS final score (Medical Oncology Physician) — 99.1275/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARK AGULNIK, MD is a Medical Oncology Physician provider practicing in LOS ANGELES, California, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1164448734. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MARK AGULNIK, MD appears in the CMS NPPES registry as a Medical Oncology Physician provider holding MD credentials at 1441 EASTLAKE AVE, LOS ANGELES, CA, 90089, with a listed phone of (323) 865-3000. NPI 1164448734 was issued on 07/15/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what AGULNIK most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 375 prescription claims written by this provider, covering 74 Medicare beneficiaries and totaling roughly $1.8 million in drug spend, split 26% brand-name and 74% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 99.1275/100 for the 2023 performance year (Quality 85.2396), compared with the national average of 83.1.

Medical Oncology Physician is a narrow specialty nationwide, with 3,792 enrolled providers across 53 states and an average of 689 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1441 EASTLAKE AVE
LOS ANGELES, CA 90089

Provider Details

NPI 1164448734
Specialty Medical Oncology Physician
Credentials MD
Gender Male
NPI Issued 07/15/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

99.1275
Final Score
Avg: 83.1
85.2396
Quality
100
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where MARK AGULNIK, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

USC CARE MEDICAL GROUP INC
ARCADIA, CA

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARK AGULNIK, MD. Source: openpaymentsdata.cms.gov.

Total received

$67.7K

Largest payer

Deciphera Pharmaceuticals Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to MARK AGULNIK, MD. To verify MARK AGULNIK, MD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

MARK AGULNIK, MD — brand share 26.0%
Specialty average (est.)

26% brand-name claims vs 74% generic, on 375 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

375
Total Claims
$1.8M
Total Drug Cost
74
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
423
Total Day Supply
10,456
Brand vs Generic
26% brand / 74% generic
Brand Drug Cost
$1.7M
Generic Drug Cost
$164K

Patient Demographics

Average Patient Age
68.3 years
Avg HCC Risk Score
2.42
Gender Split
49% female / 51% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Imatinib Mesylate
46
Votrient
Pazopanib Hcl
33
Dexamethasone
27
Ondansetron Hcl
18
Prochlorperazine Maleate
18
Lorazepam
14
Ondansetron Odt
Ondansetron
14
Furosemide
13
Spironolactone
13
Granisetron Hcl
12

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Medical Oncology Physician Overview

How MARK AGULNIK, MD fits within the Medical Oncology Physician landscape nationally.

3,792
Medical Oncology Physician Providers in US
53
States with Medical Oncology Physician
689
Avg Claims per Provider

MARK AGULNIK, MD's 375 claims are below the specialty average of 689.

Nearby Medical Oncology Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as AGULNIK.

Compare Medical Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARK AGULNIK, MD's specialty?
MARK AGULNIK, MD specializes in Medical Oncology Physician and practices in LOS ANGELES, California. Credentials: MD.
How much does MARK AGULNIK, MD prescribe under Medicare Part D?
In 2023, MARK AGULNIK, MD wrote 375 Medicare Part D claims totaling $1.8M in drug costs for 74 beneficiaries.
What is MARK AGULNIK, MD's Medicare quality score?
MARK AGULNIK, MD has a CMS MIPS Final Score of 99.1275/100 (Quality: 85.2396). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MARK AGULNIK, MD located?
MARK AGULNIK, MD is located at 1441 EASTLAKE AVE, LOS ANGELES, CA, 90089. Phone: (323) 865-3000.
What is MARK AGULNIK, MD's NPI number?
MARK AGULNIK, MD's National Provider Identifier (NPI) is 1164448734, issued on 07/15/2006.
Does MARK AGULNIK, MD prescribe more brand-name or generic drugs?
MARK AGULNIK, MD's prescribing is 26% brand-name and 74% generic drugs by claim count, with $1.7M in brand drug costs.
How many Medical Oncology Physician providers are there in the US?
There are 3,792 Medical Oncology Physician providers across 53 states in the US. The average Medical Oncology Physician provider writes 689 Medicare Part D claims per year.
What drugs does MARK AGULNIK, MD prescribe most often?
Based on 2023 Medicare Part D data, MARK AGULNIK, MD's most frequently prescribed drugs include Imatinib Mesylate, Votrient, Dexamethasone. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARK AGULNIK, MD accept Medicare?
MARK AGULNIK, MD appears in CMS Medicare data with 375 Part D claims and 74 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARK AGULNIK, MD's credentials?
MARK AGULNIK, MD's NPI is 1164448734 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology